Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer

Cancer

Volumn 116, Issue 10, 2010, Pages 2401-2408

  William Jr , William N ^a   Kies, Merrill S ^a   Fossella, Frank V ^a   Liu, Diane D ^a   Gladish, Gregory ^a   Tse, Warner H ^a   Jack Lee, J ^a   Hong, Waun K ^a   Lippman, Scott M ^a   Kim, Edward S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Bevacizumab; Carboplatin; Docetaxel; Front line; Nonsmall cell lung cancer

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; CARBOPLATIN; DOCETAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DEHYDRATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FATIGUE; FEASIBILITY STUDY; FEBRILE GRANULOCYTOPENIA; FEMALE; GRANULOCYTOPENIA; HEMOPTYSIS; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPONATREMIA; INFECTION; INTESTINE PERFORATION; LUNG EMBOLISM; LUNG HEMORRHAGE; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEINURIA; SIDE EFFECT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT RESPONSE; VOMITING; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; TAXOIDS;

EID: 77952554771     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24996     Document Type: Article

References (27)

1. Merrick DT, Haney J, Petrunich S, et al. Overexpression of vascular endothelial growth factor and its receptors in bronchial dypslasia demonstrated by quantitative RT-PCR analysis. Lung Cancer. 2005;48:31-45. (Pubitemid 40380998)
2. Yuan A, Yu CJ, Kuo SH, et al. Vascular endothelial growth factor 189 mRNA isoform expression specifically correlates with tumor angiogenesis, patient survival, and postoperative relapse in non-small-cell lung cancer. J Clin Oncol. 2001; 19:432-441.
3. Shimanuki Y, Takahashi K, Cui R, et al. Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung. 2005;183:29-42. (Pubitemid 41264745)
4. Kaya A, Ciledag A, Gulbay BE, et al. The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients. Respir Med. 2004;98: 632-636. (Pubitemid 38949927)
5. Han H, Silverman JF, Santucci TS, et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann Surg Oncol. 2001;8:72-79.
6. Fontanini G, Faviana P, Lucchi M, et al. A high vascular count and overexpression of vascular endothelial growth factor are associated with unfavourable prognosis in operated small cell lung carcinoma. Br J Cancer. 2002;86:558-563.
7. Ishii H, Yazawa T, Sato H, et al. Enhancement of pleural dissemination and lymph node metastasis of intrathoracic lung cancer cells by vascular endothelial growth factors (VEGFs). Lung Cancer. 2004;45:325-337.
8. Savai R, Langheinrich AC, Schermuly RT, et al. Evaluation of angiogenesis using micro-computed tomography in a xenograft mouse model of lung cancer. Neoplasia. 2009; 11:48-56.
9. Takayama K, Ueno H, Nakanishi Y, et al. Suppression of tumor angiogenesis and growth by gene transfer of a soluble form of vascular endothelial growth factor receptor into a remote organ. Cancer Res. 2000;60:2169-2177. (Pubitemid 30225180)
10. Kabbinavar FF, Wong JT, Ayala RE, et al. The effect of antibody to vascular endothelial growth factor and cisplatin on the growth of lung tumors in nude mice [abstract]. Proc Am Assoc Cancer Res. 1995;36:488. Abstract 2906.
11. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006;355:2542-2550. (Pubitemid 44917502)
12. Schiller JH, Harrington D, Belani CP, et al. Comparison of 4 chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346:92-98. (Pubitemid 34438899)
13. Kelly K, Crowley J, Bunn PA Jr, et al. Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non- small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19:3210-3218.
14. Scagliotti GV, De Marinis F, Rinaldi M, et al. Phase III randomized trial comparing 3 platinum-based doublets in advanced non-small-cell lung cancer. J Clin Oncol. 2002;20: 4285-4291.
15. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced nonsmall- cell lung cancer: the TAX 326 study group. J Clin Oncol. 2003;21:3016-3024.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92: 205-216.
17. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol. 2009;27:1227-1234.
18. Patel JD, Hensing TA, Rademaker A, et al. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009.
19. Waples JM, Auerbach M, Steis R, Boccia RV, Wiggans RG. A phase II study of oxaliplatin and pemetrexed plus bevacizumab in advanced non-squamous non-small cell lung cancer (An International Oncology Network study, #I-04-015) [abstract]. J Clin Oncol. 2008;26(suppl):19018.
20. Reynolds C, Barrera D, Vu DQ, et al. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2007; 25(suppl):7610.
21. Sweeney CJ, Miller KD, Sissons SE, et al. The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors. Cancer Res. 2001;61:3369-3372.
22. Pasquier E, Andre N, Braguer D. Targeting microtubules to inhibit angiogenesis and disrupt tumour vasculature: implications for cancer treatment. Curr Cancer Drug Targets. 2007;7:566-581. (Pubitemid 47358143)
23. Hotchkiss KA, Ashton AW, Mahmood R, Russell RG, Sparano JA, Schwartz EL. Inhibition of endothelial cell function in vitro and angiogenesis in vivo by docetaxel (Taxotere): association with impaired repositioning of the microtubule organizing center. Mol Cancer Ther. 2002;1: 1191-1200.
24. Vacca A, Ribatti D, Iurlaro M, et al. Docetaxel versus paclitaxel for antiangiogenesis. J Hematother Stem Cell Res. 2002;11:103-118.
25. Grant DS, Williams TL, Zahaczewsky M, Dicker AP. Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere). Int J Cancer. 2003;104:121-129. (Pubitemid 36184155)
26. Lynch TJ, Brahmer J, Fischbach N, et al. Preliminary treatment patterns and safety outcomes for non-small cell lung cancer (NSCLC) from ARIES, a bevacizumab treatment observational cohort study (OCS) [abstract]. J Clin Oncol. 2008;26:8077.
27. Miller VA, O'Connor P, Soh C, Kabbinavar F. A randomized, double-blind, placebo-controlled, phase IIIb trial (ATLAS) comparing bevacizumab (B) therapy with or without erlotinib (E) after completion of chemotherapy with B for first-line treatment of locally advanced, recurrent, or metastatic non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol. 2009;27(18S):LBA8002.